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Summary
Introduction: Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis is hypothesized to
play a role in the pathogenesis of bipolar disorder (BD). Conflicting results have been reported
when saliva or serum was used to measure cortisol levels. A recently developed method is to
measure cortisol in scalp hair, with 1 cm of scalp hair representing 1 month. We studied whether
there are differences in long-term hair cortisol levels between BD patients and healthy individuals
and whether there are associations between hair cortisol and disease characteristics.
Methods: Hair samples were collected in 100 BD patients and 195 healthy controls. Long-term
cortisol levels were determined in 3 cm hair segments. Saliva samples were collected on two
consecutive evenings. Documented disease characteristics were disease state, age of onset and
psychiatric co-morbidity.
Results: Hair cortisol levels were not statistically different in BD patients compared to healthy
controls ( p = 0.233) and were not associated with the disease state at the moment of sample
collection ( p = 0.978). In the subgroup of patients with age of onset 30 years, hair cortisol levels
were significantly elevated compared to the subgroup with age of onset <30 years and to healthy
controls ( p = 0.004). Psychiatric co-morbidity was associated with elevated cortisol levels (44.87
versus 31.41 pg/mg hair; p = 0.021), with the exclusion of panic disorder, which was associated
with decreased cortisol levels (22.13 versus 34.67 pg/mg hair; p = 0.019).
Conclusions: Elevated long-term cortisol levels might play a role in a subgroup of patients with
BD. There may be differences in pathogenesis of younger and older onset BD suggesting two
different disease entities.
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Cortisol, the main glucocorticoid in humans, is released in
response to stress as part of the hypothalamic-pituitary-
adrenal (HPA) axis that affects mineralocorticoid and gluco-
corticoid receptors throughout the brain. Dysregulation of
the HPA-axis is known to occur in several psychiatric disor-
ders, such as anxiety disorder (e.g. post-traumatic stress
disorder) (Goenjian et al., 1996) and mood disorders includ-
ing bipolar disorder (BD) (Schmider et al., 1995; Cervantes
et al., 2001; Deshauer et al., 2003; Watson et al., 2004;
Vreeburg et al., 2009; Ellenbogen et al., 2010, 2011). In
addition, depression and mania are common psychiatric
symptoms seen in patients treated with corticosteroids or
suffering from Cushing’s Syndrome, a disorder caused by
cortisol excess (Sonino and Fava, 2001; Pereira et al.,
2010). Dysregulation of the HPA-axis in BD is also supported
by several studies that have found more non-suppression
after dexamethasone (dex) administration and increased
cortisol secretion after corticotrophin releasing hormone
(CRH) in patients with BD (Watson et al., 2004; Daban
et al., 2005; Salvadore et al., 2010). However, conflicting
data have been published concerning HPA-axis dysfunction
during episodes and during euthymic phases of the disease.
Furthermore, there are only a few studies reporting dexa-
methasone suppression tests (DSTs) or combined dex/CRH
tests in patients with bipolar disorder (Watson et al., 2004;
Daban et al., 2005; Salvadore et al., 2010).
In the majority of previous studies salivary or serum
cortisol levels have been used to evaluate HPA-axis function-
ing. However, these studies yielded conflicting findings. Some
studies reported no differences in basal salivary or serum
cortisol levels in patients with BD (Watson et al., 2004;
Deshauer et al., 2006; Hardoy et al., 2006; Havermans
et al., 2011; Kamali et al., 2012), whereas others described
elevated cortisol levels (Cervantes et al., 2001; Deshauer
et al., 2003; Gallagher et al., 2007). These conflicting find-
ings might be the result of methodological differences
between the studies. Some studies reported cortisol levels
in patients in remission, while others measured cortisol levels
during active depression or mania. Furthermore, there is a
large discrepancy in the methods used to evaluate cortisol
levels in BD patients. Some studies evaluated the cortisol
awakening response, whereas others investigated diurnal
rhythms of cortisol secretion or cortisol levels at single time
points. Cortisol is secreted in a circadian rhythm and with a
pulsatile pattern, which complicates the interpretation of
serum and salivary cortisol levels. Furthermore, in blood,
only 10% of the circulating cortisol is free, 75% is bound to
cortisol binding globulin (CBG) and 10% to albumin (Carroll
et al., 2011). In most studies describing serum cortisol levels,
the concentration of CBG is not taken into account. There-
fore the concentrations of unbound, biologically active,
cortisol are not known. In addition, since cortisol is a stress
hormone, acute psychological or physical stress will also
influence serum and saliva cortisol levels. A recently devel-
oped method to measure cortisol levels in scalp hair is a
feasible method to determine long-term cortisol levels and
appears to yield a reliable estimate of long-term HPA-axis
activity (Thomson et al., 2010; Manenschijn et al., 2011).
Since hair grows with an average rate of 1 cm per month, a
hair segment of, e.g. 3 cm would reflect mean cortisol levelsover a period of approximately 3 months. This long-term
cortisol measurement is therefore not influenced by the time
of sample collection or acute stress due to daily circum-
stances or the research setting. Steudte et al. (2010) used
hair cortisol levels to measure HPA-axis activity in general-
ized anxiety disorder (GAD) and found decreased cortisol
levels in hair of patients with GAD, but no differences in
salivary cortisol levels between GAD patients and healthy
controls (Steudte et al., 2010). This suggests that hair cortisol
levels may reflect the chronic cortisol exposure, whereas the
results found with saliva or serum cortisol levels might also
include acute responses to the measurement circumstances.
Several other studies have shown that hair cortisol is indeed a
marker of long-term cortisol exposure (Kalra et al., 2007;
Sauve et al., 2007; Van Uum et al., 2008; Dettenborn et al.,
2010; Manenschijn et al., 2011).
The aim of this study was to explore the role of long-term
endogenous cortisol exposure by comparing long-term corti-
sol levels in BD patients with healthy controls using cortisol
measurements in scalp hair. We aim to obtain insight in the
long-term assessment of cortisol in patients with bipolar
disorder, since chronic subtle changes in HPA-axis functioning
appear to be involved in the pathophysiological processes
leading to mood episodes. We hypothesized that hair cortisol
levels are higher in BD patients compared to healthy indivi-
duals. In addition, we explored the relation between cortisol
levels in hair and clinical course of the disease, with char-
acteristics like disease state, age of onset, and psychiatric
co-morbidity. Furthermore, we measured saliva cortisol
levels in order to compare the observed findings of hair
cortisol.
2. Materials and methods
2.1. Study design
This is a cross-sectional study involving outpatients with BD.
The study was approved by the local medical ethics commit-
tee and is carried out in accordance with the declaration of
Helsinki. After complete description of the study to the
participants, all participants gave informed consent.
2.2. Participants
2.2.1. Bipolar disorder patients
Patients with BD (type I, type II and not otherwise specified)
included in our previous study (Spijker et al., 2011) con-
cerning the role of glucocorticoid and mineralocorticoid
receptor polymorphisms were asked to participate and
the first 100 eligible patients were included in this study.
Patients were eligible for inclusion if they had not been using
glucocorticoids in the 6 months prior to hair sample collec-
tion and if they had sufficient hair growth at the posterior
vertex. Detailed description of the assessment methods of
the patients has been described elsewhere (Spijker et al.,
2009, 2011). In brief, participants were interviewed by
trained psychologist to collect socio-demographic data
and disease characteristics. Diagnoses of BD and psychiatric
co-morbidities were based on DSM-IV criteria and were
assessed with a standardized diagnostic interview devel-
oped by Sheehan et al. (1998) using the Dutch version of
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sion 5.00-R; MINI-PLUS) (van Vliet and de Beurs, 2007). The
Questionnaire for Bipolar Illness, Dutch translation (Lever-
ich et al., 2001; Suppes et al., 2001) was used to specify
subtypes of BD, its course over time and detailed information
about age of onset of first symptoms regarding hypomanic,
manic and depressive episodes. The Questionnaire for Bipo-
lar Illness, Dutch translation is a widely used questionnaire,
developed by the National Institute of Mental Health. In
addition, detailed information was gathered to define
whether patients suffered from depression, mania or a
combined episode during the 3 months prior to hair sample
collection (this timeframe corresponds with cortisol mea-
surements in 3 cm hair segments). Based on this information,
disease state was categorized as stable disease, depressive
episode, manic episode or mixed episode. Data on age of
onset were present in 84 patients and data concerning
psychiatric co-morbidities were present in 99 patients.
2.2.2. Healthy controls
A group of 195 healthy controls were used as control group.
Detailed information of this study group has been reported
previously (Manenschijn et al., 2011). Both patients and
healthy controls filled out a questionnaire concerning hair
treatment (dyeing/bleaching/permanent waving/straigh-
tening), the use of hair products (gel, wax, hair spray) and
frequency of hair wash.
2.3. Sample collection
In all patients and healthy controls, a lock of hair of approxi-
mately 100—150 hairs was cut of from the posterior vertex as
close to the scalp as possible. Hair was taped to a paper and
stored until preparation. In addition, in 90 patients with BD
also saliva samples were collected on two consecutive eve-
nings at 2200 h. Collection at 2200 h was chosen since several
studies showed that saliva samples collected in the late
evening on separate days show the lowest variation in cortisol
levels compared to diurnal cortisol measurements and the
cortisol awakening response (Brown et al., 2008; Golden
et al., 2011; Oskis et al., 2012). This suggests that late
evening cortisol levels are slightly less influenced by acute
stressors and daily influences than, e.g. the cortisol awaken-
ing response, and may thereby be a better reflection of basal
cortisol status. Participants were instructed not to eat, drink
or brush their teeth 30 min prior to the saliva collection.
Saliva was collected by spitting into a Salicap plastic tube.
Saliva samples were stored at 20 8C until analysis. Cortisol
levels were measured separately in both saliva samples and
we calculated the mean salivary cortisol levels afterwards.
We used the mean salivary cortisol levels in the statistical
analyses.
2.4. Hair sample preparation
Hair samples were measured, weighted and put into separate
glass vials. The 3 cm segment most proximal to the scalp was
used in the analysis, which corresponds roughly to a period of
3 months. In the glass vial, hair segments were cut into small
pieces and 1 mL of methanol was added to extract cortisol
from the hair samples. After overnight incubation for 16 h at52 8C while gently shaking, the methanol was transferred to
another glass vial and was evaporated under a nitrogen
stream and the samples were dissolved in 250 mL phosphate
buffered saline (pH 8.0).
2.5. Cortisol measurement
Saliva samples were thawed and vortexed. After this, saliva
samples were centrifuged for 5 min to separate the mucins.
Cortisol in saliva as well as in the hair extracts was measured
using a commercially available salivary ELISA cortisol kit (DRG
Instruments GmbH, Marburg, Germany). Cross reactivity of
the kit’s antibodies with other steroids was reported as
follows: Corticosterone (29.00%), Cortisone (3.00%), 11-
Deoxycortisol (<1.00%), 17-OH Progesterone (<0.50%), other
hormones (<0.10%). Intra-assay variation was below 5% and
the inter-assay variation below 8% as stated by the manu-
facturer. The low-end detection limit for this assay is
1.5 nmol/L. To test the recovery of the assay, we created
cortisol standards in PBS with concentrations of 5, 10, 20, 40,
80 and 160 nmol/L and measured the recovery in duplicate.
We also spiked two hair samples with 20 nmol/L hydrocorti-
sone, to measure recovery when hydrocortisone was dis-
solved in hair extract. The recovery of 5, 10, 20, 40, 80
and 160 nmol/L cortisol standards from PBS was 96.0%,
94.0%, 94.0%, 95.0%, 96.8% and 89.9% respectively. When
hydrocortisone was added to hair extracts, the mean recov-
ery was 101.3%.
2.6. Statistical analysis
SPSS 17.0 for Windows and GraphPad 5.0 were used for
statistical analysis. Differences between group characteris-
tics were tested with Chi-square and Kruskal Wallis tests.
After log transformation hair and saliva cortisol levels were
normally distributed. Differences in cortisol levels between
healthy controls and BD patients and between disease char-
acteristics of BD patients were tested with ANCOVA and linear
regression. The association between saliva cortisol and hair
cortisol levels was tested using linear regression analysis. All
hair cortisol analyses were adjusted for gender, age, fre-
quency of hair wash, hair treatment (dyeing, bleaching,
permanent straightening or waving) and the use of hair
products. Saliva cortisol analyses were adjusted for gender
and age.
3. Results
Hair cortisol measurements were completed in 100 BD
patients and 195 healthy controls. Saliva cortisol levels were
available in 90 BD patients. Group characteristics are shown
in Table 1. All BD patients were treated in the outpatient
Department of Mood Disorders in The Hague, the Nether-
lands. BD patients were significantly older than healthy
controls and had significantly higher BMI. Furthermore, BD
patients washed their hairs less frequently and used less hair
products, but dyed/bleached their hairs more often com-
pared to the healthy control group (Table 1). The number of
patients on lithium, antidepressants, antipsychotics and
other mood stabilizers are shown in Table 1. There were
only 2 (2.0%) BD patients that did not use anti-depressants,
Figure 1 Relationship between the mean cortisol level in two evening saliva samples (collected at 2200 h) and the hair cortisol levels
on logarithmic scales. The Pearson’s correlation coefficient and its accompanying p-value are given with a regression line.
Table 1 Group characteristics.
Bipolar disorder (n = 100) Healthy controls (n = 195) p-Value
Age (years) — median (range) 52.0 (20—82) 32.0 (18—63) <0.001
Number of women — n (%) 62 (62.0%) 103 (52.8%) 0.18
BMI (kg2) — median (IQR) 25.3 (23.5—28.0) 23.7 (21.7—26.5) <0.001
Frequency of hair wash — n (%)
2 times/week 53 (53.0%) 50 (25.6%)
3 times/week 47 (47.0%) 143 (73.3%) <0.001
Hair treatmenta 40 (40.0%) 43 (22.1%) 0.001
Use of hair productsb 32 (32.0%) 90 (46.2%) 0.018
Age of onset bipolar disorder
Median (IQR) 21.0 (15.5—35.0)
<30 years of age — n (%) 55 (55%)
>30 years of age — n (%) 29 (29%)
One or more psychiatric co morbidities — n (%) 42 (42.0%)
Co morbid panic disorder 14 (14.0%)
Co morbid anxiety disorder 16 (16.0%)
Co morbid agoraphobia 21 (21.0%)
Co morbid pain disorder 1 (1.0%)
Co morbid somatoform disorder 2 (2.0%)
Medication
Lithium — n (%) 68 (68.0%)
Other mood stabilizers — n (%) 17 (17.0%)
Antidepressants — n (%) 31 (31.0%)
Antipsychotics — n (%) 34 (34.0%)
Disease state in the period covered by the hair sample
Stable disease — n (%) 43 (43.0%)
Depressive episode — n (%) 29 (29.0%)
Manic episode — n (%) 3 (3.0%)
Mixed episode — n (%) 8 (8.0%)
a Hair treatment: dyeing, bleaching, permanent waving, permanent straightening of hairs.
b Hair products: includes hair spray, wax, mouse and gel and other not wash-related hair products.
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Figure 2 Hair cortisol levels in healthy controls, bipolar disor-
der patients with younger and older age of onset. HC, healthy
controls; p-values are adjusted for age, gender, use of hair
products, hair treatment and frequency of hair wash. Error bars
represent SEM.
Figure 3 Hair cortisol and salivary cortisol levels in bipolar
disorder patients with and without co-morbid panic disorder.
Hair cortisol analyses are adjusted for age, gender, use of hair
products, hair treatment and frequency of hair wash. Saliva
cortisol analyses are adjusted for gender and age. Error bars
represent SEM.
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(30.0%) used only 1 type of medication, 31 patients (31.0%)
used 2 types of medication and 19 patients (19.0%) used 3
types of medication. There was no correlation between log-
transformed saliva cortisol and hair cortisol measurements
(b = 0.157, p = 0.140) (Fig. 1).
3.1. Hair cortisol
There were no correlations between hair cortisol levels and
age in healthy controls (r = 0.062, p = 0.39) or BD patients
(r = 0.047, p = 0.64). There were also no differences in hair
cortisol levels between men and women in healthy controls
( p = 0.87) or BD patients ( p = 0.12) and hair cortisol levels
did not correlate with BMI in BD patients (r = 0.163, p = 0.11)
or in healthy controls (r = 0.042, p = 0.59). Hair cortisol levels
in the total group of BD patients were not different from hair
cortisol levels in healthy controls (31.84 pg/mg hair (95%
Confidence interval (CI): 28.38—35.81) versus 28.18 pg/mg
hair (95% CI: 25.94—30.62); p = 0.233, adjusted for gender,
age, hair treatment, hair products and frequency of hair
wash). Since there was variability in the state of disease at
the moment of sample collection, the group of BD patients
was split up into groups with a stable period (n = 43), depres-
sive episode (n = 29), manic episode (n = 3) or combined
episode (n = 8) in the 3 months prior to sample collection.
There were no significant differences between hair cortisol
levels in the groups with various disease states in the 3
months prior to hair sample collection (unadjusted
p = 0.868; adjusted for gender, age, hair treatment, hair
products and frequency of hair wash p = 0.978). In addition,
there was no effect of lithium ( p = 0.357), other mood
stabilizers ( p = 0.388), antidepressants ( p = 0.816) or anti-
psychotics ( p = 0.278) on cortisol levels.
We found no significant correlation between age of onset
of BD (age at which the first episode of (hypo)mania or
depression presented) and hair cortisol levels (b = 0.156,
p = 0.179). However, when assessing the distribution of hair
cortisol throughout the different age of onset groups divided
in decades, we found significantly elevated hair cortisol
levels in the group of patients with their first depression
or mania 30 years of age compared to the group of patients
with their first depression or mania before 30 years of age
( p = 0.004) (Fig. 2). Hair cortisol levels in the group with
onset of BD <30 years of age were similar to those in the
healthy controls ( p = 0.886, adjusted for gender, age, hair
treatment, hair products and frequency of hair wash) (Fig. 2).
There were no differences in use of lithium ( p = 0.536), other
mood stabilizers ( p = 0.384), antidepressants ( p = 0.397) and
antipsychotics ( p = 0.278) between the group of patients
with an older age of onset of BD compared to the group of
patients with an age of onset <30 years. Furthermore, there
was no correlation between duration of the disease and hair
cortisol levels (r = 0.105, p = 0.34).
Interestingly, in patients with co-morbid panic disorder
(n = 14) hair cortisol levels were significantly lower than in BD
patients without panic disorder (22.13 versus 34.67 pg/mg
hair, p = 0.019, adjusted for gender, age, hair treatment, hair
products and frequency of hair wash) (Fig. 3). These hair
cortisol levels in patients with co-morbid panic disorder were
even lower than hair cortisol levels in healthy individuals
( p = 0.05, adjusted for gender, age, hair treatment, hairproducts and frequency of hair wash). Furthermore, we
found elevated hair cortisol levels in the group of BD patients
with other psychiatric co-morbidities (e.g. anxiety disorders,
agoraphobia, pain disorder, somatoform disorder) compared
to the BD patients without psychiatric co-morbidities
(44.87 pg/mg hair (95% CI: 34.36—58.61) versus 31.41 pg/
mg hair (95% CI: 26.06—37.76) in patients without co-mor-
bidities, p = 0.021). When patients with co-morbid panic
disorder were included in the group of total co-morbidities,
there was no significant difference in hair cortisol levels
between BD patients with and without psychiatric co-mor-
bidities anymore (34.67 versus 31.33 pg/mg, p = 0.448).
Long-term cortisol and bipolar disorder 1965Additional adjustment for BMI did not change any of the
results.
3.2. Saliva cortisol
There were no significant differences in salivary cortisol
levels between BD patients with a depressive episode, manic
episode or stable disease at the moment of saliva collection
( p = 0.304). In addition, we found no differences in salivary
cortisol levels between age of onset of disease before the age
of 30 years and after the age of 30 years ( p = 0.155). In
contrast to the results with hair cortisol levels, co-morbid
panic disorder was associated with a trend towards increased
salivary cortisol levels (5.5 (95% CI: 4.0—7.5) nmol/L versus
4.1 (95% CI: 3.6—4.7) nmol/L, unadjusted p = 0.094). How-
ever, this was not statistically significant after adjustment for
gender and age ( p = 0.245) (Fig. 3). Furthermore, we found
no differences between the group of BD patients with psy-
chiatric co-morbidities (panic disorder excluded) and with-
out psychiatric co-morbidity ( p = 0.562). Also, when panic
disorder was included in the total group of psychiatric co-
morbidities, there were no significant differences in salivary
cortisol levels between the BD patients with and without co-
morbidities ( p = 0.306). An overview of all results for hair and
salivary cortisol is given in Table 2.
4. Discussion
In this study, we measured long-term hair cortisol levels of
patients with bipolar disorder and healthy individuals. In
addition, we measured evening salivary cortisol levels in
bipolar disorder patients. The main finding of this study is
the elevated hair cortisol level in patients with older age of
onset BD compared to the group with a younger age of onset
and healthy controls. We also found that BD patients with co-
morbid psychiatric disorders (excluding panic disorder) had
higher hair cortisol levels than patients with only BD. Inter-
estingly, in patients with co-morbid panic disorder, hair corti-
sol levels were significantly decreased, whereas saliva cortisol
levels were slightly elevated. No further correlations between
hair and salivary cortisol measurements were found.
This is the first study that measured long-term hair cortisol
levels of patients with BD. Several studies have measured
cortisol levels in serum and saliva and results have been
inconclusive with reports of increased (Cervantes et al.,
2001; Deshauer et al., 2003) and normal cortisol levelsTable 2 Overview of the hair cortisol and saliva cortisol results 
Hair cortisol 
Crude b p Adjusted b 
Age of onset bipolar disorder
(<30 versus 30 years)
0.249 0.022 0.335 
Comorbid panic disorder 0.211 0.036 0.243 
Psychiatric co morbidity
(excl. panic disorder)
0.227 0.036 0.253 
Psychiatric co morbidity 0.087 0.389 0.078 
The b was calculated with linear regression. Hair cortisol analyses were
frequency of hair wash. Saliva cortisol analyses were adjusted for gen(Watson et al., 2004; Deshauer et al., 2006; Hardoy et al.,
2006; Havermans et al., 2011) compared to healthy indivi-
duals. Serum and saliva cortisol measurements reflect corti-
sol levels at one time point and are influenced by the
pulsatile pattern and circadian rhythm of cortisol secretion,
as well as by acute stress due to daily circumstances. These
limitations do not apply to hair cortisol measurements which
makes hair cortisol a better marker of HPA-axis functioning on
the long-term. Recently, two studies measured hair cortisol
levels and related them to mood disorders (Dowalti et al.,
2010; Dettenborn et al., 2012). Dettenborn et al. (2012)
showed that hair cortisol levels were elevated in medicated
patients with major depression and Dowalti et al. (2010)
showed that there was no difference in hair cortisol levels
between depressed and non-depressed patients with coron-
ary artery disease. However, hair cortisol levels of both
depressed and non-depressed patients with coronary artery
disease were higher than those in healthy controls. The
possible psychological stress associated with suffering from
coronary artery disease and the presence of coronary artery
disease itself could have abolished the differences in hair
cortisol between depressed and non-depressed patients,
resulting in different results than the observations of Detten-
born et al. Since both studies only included patients with
major depression and not BD, it is difficult to compare their
results to our findings.
In our study, we found that patients with younger (<30
years of age) and older (30 years of age) onset BD clearly
differed in their mean hair cortisol levels. Our finding of
elevated hair cortisol levels in BD patients with older age of
onset supports the hypothesis of dysfunction and hyperactivity
of the HPA-axis which has been described in BD patients and
their offspring (Holsboer et al., 1995; Schmider et al., 1995;
Ellenbogen et al., 2004, 2006, 2010; Watson et al., 2004;
Young, 2004). However, cortisol levels in patients with earlier
age of onset BD were comparable to hair cortisol levels in
healthy individuals. In the past decade, several studies have
found that there might be differences in disease character-
istics and pathogenesis of early and late onset BD. Early onset
of BD seems to be associated with greater severity and a poorer
long-term outcome (Bellivier et al., 2001; Leboyer et al.,
2005). In addition, several genetic differences have been
described between early and late onset BD (Lin et al., 2005;
Etain et al., 2006). Differences in cortisol levels and HPA-axis
functioning between subtypes of BD based on age of onset have
not been studied previously. Our hair cortisol data suggest that
elevated cortisol levels may play a role in late onset BD, but notof disease characteristics in patients with Bipolar Disorder.
Salivary cortisol
Adjusted p Crude b p Adjusted b Adjusted p
0.004 0.166 0.146 0.163 0.155
0.019 0.187 0.094 0.122 0.245
0.021 0.020 0.865 0.068 0.562
0.448 0.153 0.329 0.142 0.306
 adjusted for age, gender, use of hair products, hair treatment and
der and age.
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may be less influenced by dysregulation of the HPA-axis, but
more by other mechanisms, e.g. changing regulation of sex
hormones or differences in genetics of the disease. Later onset
of the disease might be influenced by dysregulation of the HPA-
axis through, e.g. stressful life events, which are thought to be
a trigger for manifestation of the disease (Bender and Alloy,
2011). Furthermore, it can also be hypothesized, that long-
term elevations in cortisol affect proneness for mood disorders
by neuronal damage in the brain (Oitzl et al., 2010), which may
lead to a higher risk of developing mood disorders. As seen in
patients with endogenous hypercortisolism, psychopathology
continues even after cure (Sonino and Fava, 2001; Pereira
et al., 2010), suggesting that long-term elevations in cortisol
can have irreversible effects on the brain, resulting in mood
disorders.
We did not observe these differences in age of onset with
saliva cortisol, suggesting that saliva cortisol may be an acute
marker of cortisol rather than an estimate of the HPA-axis
activity on the long-term. It supports the additional value of
measuring hair cortisol levels. Furthermore, we found no
differences in hair cortisol levels between patients in differ-
ent disease states. The same applied to the observed findings
of salivary cortisol in relation to BD, which is consistent with
several other studies (Cervantes et al., 2001; Watson et al.,
2004). This suggests that the increased HPA-axis activity may
be a trait phenomenon rather than a state phenomenon in the
subgroup of patients with older age of onset.
Moreover, we found that psychiatric co-morbidity was
associated with elevated hair cortisol levels within the group
of BD patients. With respect to the different types of co-
morbidities, we found significantly lower cortisol levels in BD
patients with co-morbid panic disorder. In contrast to this,
evening saliva cortisol levels tended to be higher in this
group. Our study is the first study that describes both hair
and saliva cortisol levels in patients with panic disorder.
These data again suggest that hair cortisol levels may reflect
cortisol levels over a larger time frame (about 3 months is this
study, since we used 3 cm length of hair), whereas saliva
cortisol may provide an estimate of one time point including
potential acute effects of the circumstances. Steudte et al.
(2010) previously demonstrated similar results in a group of
patients with generalized anxiety disorder. In this group they
found that hair cortisol levels were decreased compared to
healthy individuals, whereas there was no difference
between saliva samples of GAD patients and healthy indivi-
duals (Steudte et al., 2010). The increased saliva cortisol
levels in our BD patients with panic disorder compared to
those without comorbid panic disorder, might be explained
by more perceived stress in the participants with panic
disorder prior to a visit to the research center than BD
patients without panic disorder. Reports of saliva, serum
and urine cortisol levels in patients with panic disorder have
shown conflicting results (Kathol et al., 1989; Yehuda et al.,
1993; Bandelow et al., 2000a,b; Wedekind et al., 2000;
Vreeburg et al., 2010), which emphasizes the need for a
new reliable measurement of long-term cortisol exposure.
There are several limitations of this study. First, the
healthy individuals were significantly younger than the BD
patients, which may have affected our findings. However,
there was no effect of age on cortisol levels in the control
group (Manenschijn et al., 2011) or in the bipolar disordergroup. In addition, other studies reported no effect of age on
hair cortisol levels (Raul et al., 2004; Thomson et al., 2010;
Gao et al., 2010), and all analyses were adjusted for age.
Second, several studies have shown that other factors, such as
suicide attempts and childhood trauma can have a significant
effect on the HPA-axis (Watson et al., 2007; Kamali et al.,
2012). In our study population, there was no significant effect
of childhood abuse (sexual, physical and verbal) on hair corti-
sol levels (data not shown), but we did not collect data
concerning suicide attempts. In future studies, other factors
that might influence the HPA-axis such as childhood trauma
and suicide attempts should be taken into account as well.
Third, our study lacked data concerning smoking status
and somatic health. However, we found no differences in hair
cortisol levels between smokers and non-smokers in our
group of healthy individuals (data not shown), and a recent
study of Dettenborn et al. (2012) did not find differences in
hair cortisol levels between smokers and non-smokers as
well. Furthermore, our results of possible increased saliva
cortisol levels with decreased hair cortisol levels in patients
with panic disorder were found in a group of only 14 patients
with co-morbid panic disorder in addition to bipolar disorder.
The pathogenesis of panic disorder in BD patients might be
different from the pathogenesis of panic disorder in patients
without BD or another psychiatric disorder. Therefore, these
results have to be interpreted carefully and it is not certain
whether the results can be extrapolated to patients with
panic disorder without other psychiatric disorders. Finally,
measurement of cortisol in scalp hair is a relatively new and
promising method but many details concerning hair growth
rate and incorporation of cortisol in hair are still unknown.
Despite these limitations, our results support the hypoth-
esis that elevated long-term cortisol levels play a role in a
subgroup of patients with bipolar disorder. Since we found
that cortisol levels were only elevated in the group of
patients with a relatively late age of onset of BD, we
hypothesize that there may be differences in pathogenesis
among patients with early and late onset BD yielding two
different disease entities. Future research should focus on
exploring these subtypes of BD based on age of onset with
potentially a differential neuro-endocrine background.
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